# A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

> **NCT00975767** · PHASE1 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 126 (actual)

## Conditions studied

- Advanced Malignancies, Non-small Cell Lung Cancer

## Interventions

- **DRUG:** MGCD265+erlotinib
- **DRUG:** MGCD265+docetaxel

## Key facts

- **NCT ID:** NCT00975767
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2013-07
- **Final completion:** 2014-08
- **Target enrollment:** 126 (ACTUAL)
- **Why stopped:** The study was terminated due to a need for a reformulation of the study drug. Phase 1 completed, no patients enrolled in Phase 2.
- **Last updated:** 2015-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00975767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00975767, "A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00975767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*